Core Viewpoint - The company, Hualan Biological Engineering, emphasizes its leading position in the domestic influenza vaccine market, highlighting increased demand for flu vaccinations and its commitment to meeting this demand through enhanced supply capabilities [1] Group 1: Company Overview - Hualan Biological's subsidiary, Hualan Vaccine, is the largest influenza vaccine producer in China, with an annual production capacity of 100 million doses [1] - Since the launch of the first quadrivalent influenza virus split vaccine in 2018, the company has maintained a strong market presence, consistently ranking among the top in production and sales [1] Group 2: Production and Sales - As of 2025, the company has issued a total of 54 batches of influenza vaccines, including 48 batches of the quadrivalent influenza virus split vaccine [1] - The company has observed a significant increase in public awareness regarding flu vaccinations, leading to a notable rise in demand orders from disease control centers compared to the same period last year [1] Group 3: Market Response - In response to the heightened demand, the company is increasing its market supply of influenza vaccines and is committed to timely distribution through its cold chain logistics system to meet vaccination needs across the country [1]

Core Viewpoint - The company is advancing its drug development pipeline with promising clinical results for its diabetes treatment and is progressing towards regulatory approval for another product [1] Group 1: Drug Development - The recombinant Exendin-4-FC fusion protein injection is a long-acting GLP-1 receptor agonist for type 2 diabetes treatment, having successfully completed Phase I/II clinical trials with comprehensive efficacy and safety data [1] - The company is preparing to initiate Phase III clinical trials for the Exendin-4-FC fusion protein injection [1] Group 2: Regulatory Progress - The company's subsidiary, Hualan Gene Engineering Co., Ltd., submitted a marketing application for rituximab injection on November 22, 2024, which is currently under review by the CDE [1]

Core Viewpoint - The peak of influenza cases in China is expected to occur in mid to late December this year and early January next year, with the H3N2 subtype dominating the current flu activity [2]. Group 1: Industry Overview - The overall influenza activity in China is currently on the rise, with the H3N2 subtype accounting for over 95% of cases, alongside a small presence of H1N1 and B-type influenza viruses [2]. - The China Disease Control and Prevention Center has indicated a significant increase in public awareness regarding flu vaccinations since October, particularly in November, leading to a notable rise in demand orders from local disease control centers compared to the same period last year [2]. Group 2: Company Insights - Hualan Biological Engineering, through its subsidiary Hualan Vaccine Co., is the largest producer of influenza vaccines in China, with an annual production capacity of 100 million doses [2]. - The company has maintained a leading position in both production and sales of influenza vaccines since the introduction of the first quadrivalent influenza vaccine in 2018, emphasizing high-quality products [2]. - Hualan Biological has committed to high standards of vaccine quality control and stability monitoring, ensuring the provision of high-quality and competitively priced vaccine products [3].

Macro Strategy - In October, China's exports showed a year-on-year decline of -1.10%, marking the first negative growth since March 2025, which affected the cumulative year-on-year growth rate, decreasing from 6.10% in September to 5.30% in October. This decline is attributed to a high base in October 2024 and a temporary escalation in trade conflicts between China and the US in early October 2025 [3][4]. Market Overview - From November 3 to November 7, 2025, A-share indices experienced wide fluctuations, with the Shanghai Composite Index rising by 1.08% and the ChiNext Index increasing by 0.65%. The market is expected to continue a "slow bull" trend with wide fluctuations in November due to reduced short-term trade conflict risks between China and the US [4][5]. - Among the 31 first-level industries, the top performers were electric equipment and coal, with weekly increases of 4.98% and 4.52%, respectively. Conversely, the beauty care and computer sectors saw declines of -3.10% and -2.54% [6][7]. North Exchange Market - As of November 7, 2025, the North Exchange had 282 listed stocks, with an average total market value of 908.24 billion yuan, reflecting a 1.24% increase from the previous week. The liquidity decreased, with average trading volume dropping by 17.23% [11][12]. - The highest weekly gain was recorded by Danna Biological, which surged by 377.78% in its first week of trading, while the largest decline was seen in Beiyikang, which fell by 12.35% [13]. Vaccine Industry - The vaccine industry is experiencing structural differentiation, with companies like Kangtai Biological and Zhonghui Biological making significant advancements in vaccine development for specific populations, such as infants and pregnant women. The updated technical guidelines emphasize the importance of vaccination for high-risk groups [17][21]. - The vaccine sector's performance remains under pressure, with a year-to-date decline of -1.57%. The industry is focusing on innovation and international expansion to navigate current challenges [19][21]. - The vaccine sector's price-to-earnings ratio (PE) is currently at 99.07X, reflecting a decrease of 4.97X from the previous week, while the price-to-book ratio (PB) remains stable at 1.94X [20]. Investment Recommendations - The vaccine industry is advised to focus on innovation and international markets, as the current market conditions present challenges due to supply-demand imbalances and intense competition. Companies with strong technological capabilities and differentiated product lines are recommended for investment [21][23].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The flu virus is a highly pathogenic pathogen, emphasizing the importance of flu prevention and treatment [14] - The flu activity is on the rise, with northern regions reporting the highest number of cases in nearly four years [16] - The strategic significance of flu prevention and treatment is highlighted, with opportunities expected in the vaccine, diagnostic, and antiviral drug sectors [19] Summary by Sections Flu Virus and Its Impact - Influenza is a common respiratory infectious disease with a high transmission rate and seasonal patterns, affecting approximately 1 billion people globally each year, with 300,000 to 500,000 severe cases and 290,000 to 650,000 deaths related to respiratory diseases caused by influenza [15] - The flu activity has shown an upward trend, with the ILI% reported at 5.1% in northern provinces, exceeding levels from previous years [16] Market Performance - In the first week of November 2025, the pharmaceutical and biological sector declined by 2.4%, underperforming the CSI 300 index by 3.22 percentage points, ranking 29th among 31 sub-industries [6][26] - The pharmaceutical circulation sector saw the highest increase, up by 1.59%, while the medical research outsourcing sector experienced the largest decline, down by 4.93% [26] Investment Opportunities - The flu prevention and treatment strategy is gaining importance, with structural opportunities expected in the vaccine, diagnostic, and antiviral drug industries due to low vaccination rates and ongoing virus mutations [19] - Specific companies benefiting from the flu season include Innotest and Ansun Biologics in the in vitro diagnostics sector, Huazhong Biological in the biological products sector, and Zhongsheng Pharmaceutical in the traditional Chinese medicine sector [5] Recommended Stocks - Monthly stock recommendations include: Sanofi, Innovent Biologics, Baillie Gifford, Frontier Biologics, Haofan Biologics, Aopumai, Shanghai Yizhong, WuXi Biologics, Zai Lab, and Fangsheng Pharmaceutical [7] - Weekly stock recommendations include: Yaokang Biologics, Bidu Pharmaceuticals, Haoyuan Pharmaceuticals, China Resources Sanjiu, Huadong Medicine, Sunshine Nuohuo, Yuekang Pharmaceuticals, Zhongsheng Pharmaceuticals, and Jichuan Pharmaceuticals [7]

Investment Rating - The industry investment rating is maintained at "Overweight" [2][9]. Core Insights - The vaccine industry is currently transitioning from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term outlook remains positive driven by policy, demand, and technology [8][9][28]. - Recent breakthroughs in vaccine development for specific populations, such as the quadrivalent influenza vaccine for infants and pregnant women, highlight ongoing innovation in the sector [4][8][9]. - The industry is experiencing structural differentiation among companies, with a focus on innovative and multi-valent products to enhance competitiveness [8][9]. Market Performance - The vaccine sector saw a slight increase of 0.04% last week, while the overall pharmaceutical sector declined by 2.4% [5][11]. - Year-to-date, the vaccine sector has experienced a cumulative decline of 1.57% [5][11]. Company Developments - Companies like Kangtai Biological and Zhonghui Biological are making significant progress in vaccine trials for specific demographics, which could fill market gaps [4][8]. - The latest technical guidelines emphasize the importance of vaccination for high-risk groups, which may drive demand for vaccines [4][8]. Valuation Metrics - The vaccine sector's price-to-earnings (PE) ratio is 99.07X, down 4.97X from the previous period, indicating a high valuation relative to historical standards [7][20]. - The price-to-book (PB) ratio stands at 1.94X, remaining stable, with historical maximum and minimum values of 2.29X and 1.69X respectively [7][20]. Investment Recommendations - The report suggests focusing on companies with strong R&D capabilities and differentiated product offerings, recommending Kangxino and Kanghua Biological as key players to watch [9][28].

Group 1 - MSCI announced changes to its indices on November 6, including the addition of 17 A-shares and the removal of 16 A-shares, effective after the market close on November 24 [1] - Newly added A-shares include companies such as Qianli Technology, Dongyangguang, and Changchuan Technology, while removed A-shares include names like Zhongzhi Co., Bertli, and Dong'a Ejiao [1] - In addition to A-shares, the MSCI China Index also added 9 Hong Kong stocks, including Zijin Mining International and GF Securities, while removing 4 stocks such as Beikong Water Group and China Everbright Bank [1] Group 2 - The largest newly added stocks in the MSCI Global Standard Index include CoreWeave, Nebius Group, and Insmed, while the largest in the MSCI Emerging Markets Index are Barito Renewables Energy, Zijin Mining International, and GF Securities [2] - MSCI conducts four routine adjustments to its indices annually, with the May and November adjustments being more significant compared to the smaller adjustments in February and August [2]

Core Viewpoint - The Ministry of Industry and Information Technology (MIIT) has announced the list of selected units for the high-performance bioreactor innovation task, aiming to enhance the supply capacity of key equipment for biological manufacturing [2][3]. Summary by Relevant Sections Task Objectives - The initiative focuses on three categories: reactor systems, key components and consumables, and industrial operating systems, with a total of nine tasks aimed at selecting and nurturing units with strong innovation capabilities and mastery of core technologies [2]. Selected Units - Notable units included in the list are: - Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences - Guangzhou Aibaitai Biotechnology - Shanghai Dongfulong - Jiangsu Weiji Wisdom - Shanghai Shunyu Hengping - Shanghai Ailite [5][6]. Task Directions - The tasks cover various directions such as: 1. Microbial parallel bioreactors 2. Cell parallel bioreactors 3. Large cell bioreactors 4. Core physicochemical parameter in-situ monitoring 5. Biological reactor intelligent industrial operating systems [5][6]. Innovation Goals - The goal is to break through several landmark technologies, cultivate typical application scenarios, and accelerate the landing and application of new technologies and products, thereby enhancing the integrated development capability of high-performance bioreactors [2].

Group 1 - The core point of the article highlights that Hualan Biological experienced a closing price increase of 0.92% to 16.46 yuan, with a significant block trade occurring on November 7, totaling 1.3 million shares and a transaction value of 21.398 million yuan [1] - The first transaction was executed at a price of 16.46 yuan for 1.3 million shares, with a premium rate of 0.00%. The buyer was an institutional entity, while the seller was China International Capital Corporation's Shanghai branch [1] - Over the past three months, there has been only one block trade for this stock, with a total transaction value of 21.398 million yuan. In the last five trading days, the stock has risen by 2.11%, but there has been a net outflow of 21.6853 million yuan in principal funds [1]

Group 1 - On November 7, Hualan Biological completed a block trade of 1.3 million shares, with a transaction value of 21.398 million yuan, accounting for 6.49% of the total trading volume for the day [1][2] - The transaction price was 16.46 yuan per share, which was in line with the market closing price of 16.46 yuan [1][2]